112 related articles for article (PubMed ID: 12659747)
1. Syntheses of novel diphenyl piperazine derivatives and their activities as inhibitors of dopamine uptake in the central nervous system.
Kimura M; Masuda T; Yamada K; Mitani M; Kubota N; Kawakatsu N; Kishii K; Inazu M; Kiuchi Y; Oguchi K; Namiki T
Bioorg Med Chem; 2003 Apr; 11(8):1621-30. PubMed ID: 12659747
[TBL] [Abstract][Full Text] [Related]
2. Novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter.
Kimura M; Masuda T; Yamada K; Mitani M; Kubota N; Kawakatsu N; Kishii K; Inazu M; Kiuchi Y; Oguchi K; Namiki T
Bioorg Med Chem; 2003 Sep; 11(18):3953-63. PubMed ID: 12927856
[TBL] [Abstract][Full Text] [Related]
3. Efficient asymmetric syntheses, determination of absolute configurations and biological activities of 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-hydroxy-3-(phenylamino)propyl]piperazine as a novel potent dopamine uptake inhibitor in the central nervous system.
Kimura M; Masuda T; Yamada K; Mitani M; Kubota N; Kawakatsu N; Kishii K; Inazu M; Kiuchi Y; Oguchi K; Namiki T
Bioorg Med Chem; 2004 Jun; 12(11):3069-78. PubMed ID: 15142566
[TBL] [Abstract][Full Text] [Related]
4. Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine.
Hsin LW; Dersch CM; Baumann MH; Stafford D; Glowa JR; Rothman RB; Jacobson AE; Rice KC
J Med Chem; 2002 Mar; 45(6):1321-9. PubMed ID: 11882001
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909).
Zhang Y; Rothman RB; Dersch CM; de Costa BR; Jacobson AE; Rice KC
J Med Chem; 2000 Dec; 43(25):4840-9. PubMed ID: 11123994
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of newly developed iodinated 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]piperazine derivatives in rats: limited value as dopamine transporter SPECT ligands.
Rijks LJ; Booij J; Doornbos T; Boer GJ; Ronken E; de Bruin K; Vermeulen RJ; Janssen AG; Van Royen EA
Synapse; 1996 Jul; 23(3):201-7. PubMed ID: 8807748
[TBL] [Abstract][Full Text] [Related]
7. Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats.
Nakachi N; Kiuchi Y; Inagaki M; Inazu M; Yamazaki Y; Oguchi K
Eur J Pharmacol; 1995 Aug; 281(2):195-203. PubMed ID: 7589207
[TBL] [Abstract][Full Text] [Related]
8. Antioxidative activities of novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter.
Kimura M; Masuda T; Yamada K; Kawakatsu N; Kubota N; Mitani M; Kishii K; Inazu M; Kiuchi Y; Oguchi K; Namiki T
Bioorg Med Chem Lett; 2004 Aug; 14(16):4287-90. PubMed ID: 15261288
[TBL] [Abstract][Full Text] [Related]
9. GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine.
Rothman RB; Mele A; Reid AA; Akunne HC; Greig N; Thurkauf A; de Costa BR; Rice KC; Pert A
Pharmacol Biochem Behav; 1991 Oct; 40(2):387-97. PubMed ID: 1839568
[TBL] [Abstract][Full Text] [Related]
10. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909).
Matecka D; Rothman RB; Radesca L; de Costa BR; Dersch CM; Partilla JS; Pert A; Glowa JR; Wojnicki FH; Rice KC
J Med Chem; 1996 Nov; 39(24):4704-16. PubMed ID: 8941383
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and preliminary characterization of a high-affinity novel radioligand for the dopamine transporter.
Dutta AK; Reith ME; Madras BK
Synapse; 2001 Feb; 39(2):175-81. PubMed ID: 11180505
[TBL] [Abstract][Full Text] [Related]
12. Identification of a GBR12935 homolog, LR1111, which is over 4,000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters.
Rothman RB; Lewis B; Dersch C; Xu H; Radesca L; de Costa BR; Rice KC; Kilburn RB; Akunne HC; Pert A
Synapse; 1993 May; 14(1):34-9. PubMed ID: 8511716
[TBL] [Abstract][Full Text] [Related]
13. Discovery of substituted 3,4-diphenyl-thiazoles as a novel class of monoamine transporter inhibitors through 3-D pharmacophore search using a new pharmacophore model derived from mazindol.
Enyedy IJ; Wang J; Zaman WA; Johnson KM; Wang S
Bioorg Med Chem Lett; 2002 Jul; 12(13):1775-8. PubMed ID: 12067559
[TBL] [Abstract][Full Text] [Related]
14. Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents.
Lewis DB; Matecka D; Zhang Y; Hsin LW; Dersch CM; Stafford D; Glowa JR; Rothman RB; Rice KC
J Med Chem; 1999 Dec; 42(24):5029-42. PubMed ID: 10585212
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.
Husbands SM; Izenwasser S; Kopajtic T; Bowen WD; Vilner BJ; Katz JL; Newman AH
J Med Chem; 1999 Oct; 42(21):4446-55. PubMed ID: 10543888
[TBL] [Abstract][Full Text] [Related]
16. Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors.
Matecka D; Lewis D; Rothman RB; Dersch CM; Wojnicki FH; Glowa JR; DeVries AC; Pert A; Rice KC
J Med Chem; 1997 Feb; 40(5):705-16. PubMed ID: 9057857
[TBL] [Abstract][Full Text] [Related]
17. Tight binding dopamine reuptake inhibitors as cocaine antagonists. A strategy for drug development.
Rothman RB; Mele A; Reid AA; Akunne H; Greig N; Thurkauf A; Rice KC; Pert A
FEBS Lett; 1989 Nov; 257(2):341-4. PubMed ID: 2583282
[TBL] [Abstract][Full Text] [Related]
18. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and binding properties of [3H]NNC 12-0781, a new radioligand for the dopamine reuptake system.
Müller L; Hall H; Halldin C; Farde L; Hohlweg R; Suzdak PD; Nielsen EB; Foged C
Nucl Med Biol; 1995 Aug; 22(6):711-7. PubMed ID: 8535331
[TBL] [Abstract][Full Text] [Related]
20. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat.
Mazei MS; Pluto CP; Kirkbride B; Pehek EA
Brain Res; 2002 May; 936(1-2):58-67. PubMed ID: 11988230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
